A breakthrough trial suggests that MDMA-assisted therapy is both safe and effective for people with post-traumatic stress disorder (PTSD).
The first Phase 3 trial of MDMA-assisted therapy for PTSD replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
Nature Medicine is expected to publish the peer-reviewed paper detailing the results of the study sponsored by the Multidisciplinary Association of Psychedelic Studies (MAPS) and conducted by MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of MAPS. In this first Phase 3 trial of any psychedelic-assisted therapy, participants who received MDMA-assisted therapy reported a significant reduction in PTSD symptoms compared to those who received placebo with therapy (p<0.0001), successfully achieving the prespecified primary endpoint for the trial. In fact, 67% of the group who received MDMA, compared to 32% of the group who received placebo, no longer qualified for a PTSD diagnosis after three treatment sessions. In addition, participants treated with MDMA-assisted therapy had statistically significant reductions for the key secondary endpoint of functional impairment relative to placebo with therapy (p=0.0116).
Jennifer Mitchell, Ph.D., lead author of the paper, calls attention to the results for those with the dissociative subtype of PTSD, with depression, or who reported a history of alcohol or substance use. People with the most difficult-to-treat diagnoses, often considered intractable, respond just as well to this novel treatment as other study participants. In fact, participants diagnosed with the dissociative subtype of PTSD experienced a greater reduction in symptoms than those without the dissociative subtype.
Mitchell added that MDMA serves as a catalyst to therapy: MDMA is an experiential therapeutic and therefore necessitates the appropriate set and setting to truly guide change and recovery. While many forms of PTSD therapy involve recalling previous trauma, the unique ability of MDMA to raise compassion and understanding while tamping down fear is likely what enables it to be so effective.
The randomized, blinded, Phase 3 trial, designed under a Special Protocol Assessment with the FDA, treated 90 patients with severe, chronic PTSD. Participants were randomized to receive three sessions of either MDMA or placebo with identical talk therapy. Forty-six participants received MDMA therapy and forty-four participants received therapy with placebo. The primary efficacy endpoint was based on the change from baseline in an independently assessed clinical interview of PTSD severity after 18 weeks. The assessors also measured average change in functional impairment in work/school, social, and family life. Among the participants in the MDMA-assisted therapy group, 67% no longer qualified for PTSD diagnosis after three MDMA-assisted therapy sessions and 88% of participants experienced a clinically significant reduction in symptoms, while in the placebo group, 32% no longer qualified for PTSD diagnosis at the two-month follow-up and 60% experienced a clinically significant reduction in symptoms.
In the Phase 3 trial, the investigators observed no serious safety or tolerability issues in the MDMA group. MDMA did not increase the risk of suicidal thoughts or behaviors and did not increase cardiovascular risk or abuse potential relative to therapy with placebo. As expected from previous clinical trials, temporary increases in blood pressure and pulse were observed during MDMA sessions; adverse events such as muscle tightness, decreased appetite, nausea, sweating, and feeling cold were transient.
PTSD is a profoundly challenging condition with unmet medical need. Bessel van der Kolk, M.D., a leading PTSD researcher and author of the foundational book on PTSD, The Body Keeps the Score, served as Principal Investigator for the Boston study site. He explains, The experience of having been traumatized profoundly alters perceptions; self-experience; and capacity to plan, imagine and anticipate. For 88% of people who receive this treatment, we can expect to see a treatment response. This can lead to fundamental shifts in our subjects' perspective on self-capacity, affect regulation, and attitude towards those around them. It takes a great deal of courage to address ones PTSD, particularly when other treatments have failed. These results open the door to a potentially powerful new pathway to healing -- once MDMA-assisted therapy has been approved as a treatment for PTSD.
Listed as a Schedule I drug, MDMA presently is defined as having no medical benefit and, therefore, is not currently accessible as a potential treatment for PTSD or other conditions except as administered in clinical trials. As a result of this study and through the persistent and consistent application of scientific rigor, we have demonstrated that MDMA-assisted therapy is likely to provide relief for people diagnosed with PTSD, noted MAPS Executive Director Rick Doblin, Ph.D. Far from having no medical benefit, MDMA, when combined with talk therapy in this protocol, has the potential to catalyze the therapeutic process and generate positive mental health outcomes.
Michael Mithoefer, M.D., who serves as Senior Medical Director for Medical Affairs, Training, and Supervision, led the team that developed the therapy manual and trained the 70 therapists who provided the treatment in the Phase 3 study. He celebrated their efforts, stating, The therapists and expert research team who have brought us here are at the vanguard of what may be a revolution in mental health care. The success of this pivotal study is a major step toward regulatory approval, and we hope these results will attract many more researchers and clinicians to join the effort to further explore and deliver MDMA-assisted therapy so we can together address our national and global mental health crisis.
MAPS PBC develops and delivers therapy training programs and is responsible for the development of MDMA as a medicine. MAPS PBC CEO Amy Emerson describes its mandate: MAPS Public Benefit Corporation is establishing a new paradigm in drug research, development, and commercialization in which we center our efforts wholly on the beneficiaries of our healing modality rather than shareholders. This approach commits us to open science and open books as we research best practices for psychedelic-assisted therapy. Ultimately, any proceeds from our work will be reinvested to generate more research, more training, and more affordable options for treatment.
A second Phase 3 clinical trial is currently enrolling participants. Prior to the hopeful approval in 2023 of MDMA-assisted therapy for PTSD, the FDA has granted permission for an expanded access program in which 50 patients can receive the treatment prior to FDA approval. MAPS plans to conduct additional studies to explore the potential of the treatment for other mental health conditions and with other treatment protocols such as group therapy and cognitive-behavioral conjoint therapy for couples. Additionally, MAPS is funding a formal commitment to health equity: a holistic plan to create more pathways to access MDMA-assisted therapy for those historically marginalized by the mental health field and society at large.
Reference: Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. Published online May 10, 2021:1-9. doi:10.1038/s41591-021-01336-3
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
Read the original here:
MDMA-Assisted Therapy Effective at Treating PTSD, Finds Breakthrough Trial - Technology Networks
- 7 Reasons to Retire and Relocate When Savings Fall Short ... - ThinkAdvisor - October 9th, 2023 [October 9th, 2023]
- Strive Asset Management vs. Engine No. 1: How Did the Activists ... - Morningstar - September 21st, 2023 [September 21st, 2023]
- New Taskforce to build UK nuclear skills - GOV.UK - July 31st, 2023 [July 31st, 2023]
- National Bank of Canada FI Has $16.22 Million Position in ... - Defense World - June 26th, 2023 [June 26th, 2023]
- RIT part of National Science Foundation grant to help spur next ... - Rochester Institute of Technology - May 22nd, 2023 [May 22nd, 2023]
- 2023 NAIA Outdoor Track & Field Regional Awards - U.S. Track & Field and Cross Country Coaches Association - May 22nd, 2023 [May 22nd, 2023]
- P&I wins ASBPE national gold award for managers microsite - Pensions & Investments - May 22nd, 2023 [May 22nd, 2023]
- The National - January 30th, 2023 [January 30th, 2023]
- Dimon Highlights Need For More Oil And Gas Investment As Vanguard Bails On ESG Group - Forbes - December 16th, 2022 [December 16th, 2022]
- About Us | National Vanguard - November 19th, 2022 [November 19th, 2022]
- Vanguard News Network - October 11th, 2022 [October 11th, 2022]
- Retirement Clearinghouse Announces Auto-Portability Network with Fidelity, Vanguard and Alight | PLANSPONSOR - PLANSPONSOR - October 11th, 2022 [October 11th, 2022]
- Abenaa Jones named Ann Atherton Hertzler Early Career Professor - Pennsylvania State University - August 6th, 2022 [August 6th, 2022]
- City of Detroit, Charles H. Wright Museum of African American History, join the Black Theatre Network (BTN) to host Broadway Comes Home to Detroit, a... - July 25th, 2022 [July 25th, 2022]
- California Senate Votes to Keep Legalized Slavery in its Prisons - The Peoples Vanguard of Davis - June 29th, 2022 [June 29th, 2022]
- Schneider National (NYSE:SNDR) Now Covered by Analysts at Credit Suisse Group - Defense World - June 29th, 2022 [June 29th, 2022]
- Introducing the Truckstop.com Partner Marketplace: A Comprehensive Transportation and Logistics Ecosystem Empowering the Freight Community - Yahoo... - June 29th, 2022 [June 29th, 2022]
- A Pilgrimage to the Birthplace of the Modern Womens Rights Movement - AFAR Media - June 29th, 2022 [June 29th, 2022]
- White Child Adopted by Black Reality TV Star Beaten to Death - June 24th, 2022 [June 24th, 2022]
- National Car Rental - Wikipedia - June 24th, 2022 [June 24th, 2022]
- Down 15% in 2022, is it time to jump on Vanguard Australian Shares Index ETF? - The Motley Fool Australia - June 24th, 2022 [June 24th, 2022]
- LIVE BLOG: 2022 Corps at the Crest - San Diego - FloMarching - June 24th, 2022 [June 24th, 2022]
- Greater Sacramento Attends Bio International Convention in San Diego - The Peoples Vanguard of Davis - June 22nd, 2022 [June 22nd, 2022]
- Vanguard International Semiconductor : VIS and National Yang Ming Chiao Tung University Cofound Intelligent Manufacturing and Management Laboratory -... - June 22nd, 2022 [June 22nd, 2022]
- The Shadow Of June 12 - The Left and Nigeria's Democratic Revolution, By Baba Aye - SaharaReporters.com - June 22nd, 2022 [June 22nd, 2022]
- Yolo County Honors Juneteenth with Celebration - The Peoples Vanguard of Davis - June 22nd, 2022 [June 22nd, 2022]
- Commentary: Why San Francisco May Not Be the Best Test Case for Progressivism - The Peoples Vanguard of Davis - June 22nd, 2022 [June 22nd, 2022]
- As tennis fans gather Wimbledon worries expansion won't get over the line - The National - June 22nd, 2022 [June 22nd, 2022]
- Vanguard Charitable survey: More than 1 in 3 American donors gave half or more of their charitable contributions to disaster relief efforts in the... - May 20th, 2022 [May 20th, 2022]
- National Grid warns on cost-of-living challenges after strong profit (NYSE:NGG) - Seeking Alpha - May 20th, 2022 [May 20th, 2022]
- Is it a good time to buy the Vanguard Australian Shares Index ETF? - The Motley Fool Australia - May 20th, 2022 [May 20th, 2022]
- Student Opinion: The Biden Administration and Cable Companies Working Together to Bring Internet to Millions of Households - The Peoples Vanguard of... - May 20th, 2022 [May 20th, 2022]
- THE POWER OF LEADERSHIP - THISDAY Newspapers - May 20th, 2022 [May 20th, 2022]
- Vanguard may be shorting much vaunted 'owners' of its low-cost index funds as it upshifts to more Wall Street-style exec-comp tactics to thwart... - May 17th, 2022 [May 17th, 2022]
- Opinion | BlackRock, Vanguard and State Street Control a Piece of Nearly Everything - The New York Times - May 17th, 2022 [May 17th, 2022]
- Somalis receive explosive threat reduction training | Shephard - Shephard News - May 17th, 2022 [May 17th, 2022]
- JV Article: Platinum Group Metals is at the vanguard of next generation lithium-ion batteries - The Northern Miner - May 17th, 2022 [May 17th, 2022]
- Neo-Nazi Alex Davies guilty of belonging to banned terror group National Action - Tell MAMA - May 17th, 2022 [May 17th, 2022]
- Firearm-Related Homicides Reach an Unprecedented Level in the 21st Century - The Peoples Vanguard of Davis - May 17th, 2022 [May 17th, 2022]
- Satellites, the Space Race, and Supercomputing: How NASA Goddard's Beowulf Cluster Computer Became an Award-Winning Space Technology - NASA (.gov) - May 17th, 2022 [May 17th, 2022]
- Vanguard may be shorting much vaunted 'owners' of its low-cost index funds as it shifts to Wall Street-style exec-comp tactics to thwart competitors... - May 15th, 2022 [May 15th, 2022]
- Senate Democrats Fail to Codify Abortion Rights; Don't Have Votes to Overcome Filibuster Dem Manchin Votes with GOP - The Peoples Vanguard of Davis - May 15th, 2022 [May 15th, 2022]
- The School Buzz: Vanguard rocketry team competing for national title - KRDO - May 9th, 2022 [May 9th, 2022]
- The Anglo-Indian-Nigerian designer at the vanguard of British fashion - The National - May 9th, 2022 [May 9th, 2022]
- Candidate for Yolo County District Attorney Cynthia Rodriguez Announced Her Growing List of Endorsements in a Press Release on Thursday - The Peoples... - May 9th, 2022 [May 9th, 2022]
- Commentary: Trends Are Pushing Tech, Housing Toward Sacramento Region - The Peoples Vanguard of Davis - May 9th, 2022 [May 9th, 2022]
- UK Government announces 2 billion investment into nuclear submarines - The National - May 9th, 2022 [May 9th, 2022]
- Workers grapple with new stresses as they return to office - Tampa Bay Times - May 9th, 2022 [May 9th, 2022]
- Who is Ib Kamara, the new Off-White art director to fill Virgil Abloh's shoes? - The National - May 9th, 2022 [May 9th, 2022]
- Vanguard Lions Defeat Statesmen To End The Year - Victory Sports Network - April 15th, 2022 [April 15th, 2022]
- Other days - Arkansas Online - April 15th, 2022 [April 15th, 2022]
- Democrats are in danger of losing three congressional strongholds in South Texas - Standard-Times - April 15th, 2022 [April 15th, 2022]
- Remembering the WNBA's Portland Fire - Vanguard - Psuvanguard.com - April 13th, 2022 [April 13th, 2022]
- Honoring the life of Amara Marluke - Vanguard - Psuvanguard.com - April 13th, 2022 [April 13th, 2022]
- The grim outlook of owning and renting - Vanguard - Psuvanguard.com - April 13th, 2022 [April 13th, 2022]
- 2022 NAIA Women's Outdoor Track & Field Rating Index Week 3 - U.S. Track & Field and Cross Country Coaches Association - April 13th, 2022 [April 13th, 2022]
- ECOWAS and Nigeria Agree on a Roadmap to Institutionalise a Government and Society Wide Approach - African Business - March 17th, 2022 [March 17th, 2022]
- LA Treasurer joins other states in divesting Russian investments - KATC News - March 8th, 2022 [March 8th, 2022]
- How the US and Europe helped Ukraine prep for insurgency - ArmyTimes.com - March 8th, 2022 [March 8th, 2022]
- A Trailblazing Engineer Says Invention Is in Everything I Do - Tufts Now - March 8th, 2022 [March 8th, 2022]
- Russias Invasion of Ukraine and Implications for the Korean Peninsula - Council on Foreign Relations - March 8th, 2022 [March 8th, 2022]
- Vanguard University saying goodbye to the Pit - Los Angeles Times - January 14th, 2022 [January 14th, 2022]
- Energy Ended Up as a Good Bet Last Year. But Now What? - The New York Times - January 14th, 2022 [January 14th, 2022]
- Kensington Vanguard National Land Services - December 19th, 2021 [December 19th, 2021]
- Barry Harris, Pianist and Devoted Scholar of Bebop, Dies at 91 - The New York Times - December 10th, 2021 [December 10th, 2021]
- From Our Archives: a Profile of Bob Dole, Once the Senate's "Funniest Member" - Washingtonian - December 7th, 2021 [December 7th, 2021]
- National Auto Care on acquisition spree amid F&I consolidation - Automotive News - December 5th, 2021 [December 5th, 2021]
- A decade of marketisation has left lecturers with no choice but to strike - The Guardian - December 5th, 2021 [December 5th, 2021]
- A New Vanguard Is Reshaping the Art World - HarpersBAZAAR.com - December 5th, 2021 [December 5th, 2021]
- Opinion | The Trump Conspiracy Is Hiding in Plain Sight - The New York Times - December 5th, 2021 [December 5th, 2021]
- The forgotten importance of the War of Jenkins' Ear - The Economist - December 5th, 2021 [December 5th, 2021]
- What Conservative Critics of Higher Education Share - The Atlantic - December 5th, 2021 [December 5th, 2021]
- The Unite the Right trial is exposing the chasm between who plans White nationalism's battles and who does the fighting - ABC17News.com - November 19th, 2021 [November 19th, 2021]
- Tordue Salem: Journalists ask National Assembly to order independent inquiry into death of missing reporter - Premium Times - November 19th, 2021 [November 19th, 2021]
- Abu Dhabi to Welcome Two New Museums in Addition to Guggenheim and Zayed - Artforum - November 19th, 2021 [November 19th, 2021]
- Gauteng government at the vanguard of SAs green economy plans - Business Day - November 17th, 2021 [November 17th, 2021]
- 25 years of school and family connections | Hub - The Hub at Johns Hopkins - November 17th, 2021 [November 17th, 2021]
- Opinion: Organized crime is a top driver of global deforestation and climate change - Houston Chronicle - November 17th, 2021 [November 17th, 2021]
- Letters to the editor: Lend a hand to these family caregivers - Austin American-Statesman - November 15th, 2021 [November 15th, 2021]
- University of Chicago to award four honorary degrees at 2022 Convocation - UChicago News - November 9th, 2021 [November 9th, 2021]